Revision as of 16:52, 16 July 2021 editJJMC89 bot III (talk | contribs)Bots, Administrators3,685,176 editsm Moving Category:Heterocyclic compounds (2 rings) to Category:Heterocyclic compounds with 2 rings per Misplaced Pages:Categories for discussion/Log/2021 June 24#Category:Heterocyclic compounds (1 ring)← Previous edit | Revision as of 14:09, 16 April 2022 edit undoVortioxetine (talk | contribs)Extended confirmed users1,175 editsm Added SVG of structureNext edit → | ||
Line 4: | Line 4: | ||
| verifiedrevid = 443223642 | | verifiedrevid = 443223642 | ||
| IUPAC_name = 2-(8,9-Dioxo-2,6-diazabicyclonon-1(7)-en-2-yl)ethylphosphonic acid | | IUPAC_name = 2-(8,9-Dioxo-2,6-diazabicyclonon-1(7)-en-2-yl)ethylphosphonic acid | ||
| image = Perzinfotel. |
| image = Perzinfotel.svg | ||
| width = |
| width = 150 | ||
<!--Clinical data--> | <!--Clinical data--> |
Revision as of 14:09, 16 April 2022
Pharmaceutical compoundClinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.222.780 |
Chemical and physical data | |
Formula | C9H13N2O5P |
Molar mass | 260.186 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Perzinfotel (EAA-090) is a drug which acts as a potent NMDA antagonist. It has neuroprotective effects and has been investigated for the treatment of stroke, but lacks analgesic effects. Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.
References
- Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, et al. (January 1998). "Design and synthesis of non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere". Journal of Medicinal Chemistry. 41 (2): 236–46. doi:10.1021/jm970504g. PMID 9457246.
- Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, et al. (August 2004). "Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride)". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 563–70. doi:10.1124/jpet.104.066092. PMID 15075380. S2CID 25505657.
- Brandt MR, Cummons TA, Potestio L, Sukoff SJ, Rosenzweig-Lipson S (June 2005). "Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1379–86. doi:10.1124/jpet.105.084467. PMID 15764736. S2CID 12989500.
- "Perzinfotel". Adis International Ltd. Springer Nature Switzerland AG.
- Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, et al. (February 2009). "Prodrugs of perzinfotel with improved oral bioavailability". Journal of Medicinal Chemistry. 52 (3): 771–8. doi:10.1021/jm8011799. PMID 19146418.
Ionotropic glutamate receptor modulators | |
---|---|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |